Changes in liver steatosis in HIV-positive women are associated with the BMI, but not with biomarkers.
ART
CAP
HIV
Liver Steatosis
NAFL
Journal
Cytokine
ISSN: 1096-0023
Titre abrégé: Cytokine
Pays: England
ID NLM: 9005353
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
05
11
2020
revised:
28
04
2021
accepted:
30
04
2021
pubmed:
18
5
2021
medline:
5
2
2022
entrez:
17
5
2021
Statut:
ppublish
Résumé
The prevalence of non-alcoholic fatty liver disease (NAFLD) is higher in HIV-infected patients compared to the general population. While metabolic risk factors such as obesity, insulin resistance and the metabolic syndrome have been identified as key risk factors in all individuals, there is limited information regarding the mechanisms that contribute to the higher prevalence among individuals living with HIV, particularly among women and ethnic minorities. The aim of this study was to determine the association, over two time points, of a panel of biomarkers with liver steatosis in a cohort of HIV-seropositive women and age-matched negative controls and to investigate whether the association differed by HIV status. To this effect, plasma samples obtained from 105 HIV-positive and -negative participants enrolled in the Women's Interagency HIV study (WIHS) Washington DC site were assayed for biomarkers associated with inflammation, adipose tissue function, fibrinolysis, gut permeability and hepatocyte apoptosis/necrosis. Their association with liver steatosis, measured using Controlled-Attenuation Parameter (CAP) scores determined by transient elastography, were then analyzed. HIV positivity was associated with lower median IL-17A and higher IL-22 and sCD14 values. There were no statistically significant associations between HIV status, biomarkers or covariates with CAP measurement over two time points. However, IL-1β levels were associated with higher CAP scores at the second visit. Across all statistical models, an increase in BMI was associated with an increase in CAP measurements. No statistically significant associations were found between viral load history, CD4 + T-cell count, biomarkers and covariates, including ART use, on CAP measurements. These results confirm that BMI is a key risk factor for liver steatosis independent of HIV status. The potential contributions to NAFLD of differences in IL-1β, Th17-family cytokines and gut permeability between HIV-positive vs. negative individuals require further study.
Identifiants
pubmed: 33994069
pii: S1043-4666(21)00156-3
doi: 10.1016/j.cyto.2021.155573
pmc: PMC8607847
mid: NIHMS1754393
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
155573Subventions
Organisme : NIAID NIH HHS
ID : P30 AI027767
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146205
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI117970
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146193
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000004
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Mucosal Immunol. 2012 Nov;5(6):670-80
pubmed: 22854709
J Infect Dis. 2011 Mar 15;203(6):780-90
pubmed: 21252259
QJM. 2010 Feb;103(2):71-83
pubmed: 19914930
JAMA Netw Open. 2019 May 3;2(5):e193822
pubmed: 31099865
Epidemiology. 1998 Mar;9(2):117-25
pubmed: 9504278
Clin Infect Dis. 2020 Sep 12;71(6):1379-1389
pubmed: 31606734
Pediatr Infect Dis J. 2011 Oct;30(10):877-82
pubmed: 21552185
Curr Opin Lipidol. 2007 Jun;18(3):240-5
pubmed: 17495595
Clin Infect Dis. 2017 Oct 30;65(10):1695-1702
pubmed: 29020239
AIDS. 2017 Jan 28;31(3):365-373
pubmed: 27831949
J Infect Dis. 2020 Sep 14;222(8):1353-1362
pubmed: 32417886
Dig Liver Dis. 2016 Dec;48(12):1471-1477
pubmed: 27623186
Medicine (Baltimore). 2016 Nov;95(46):e5399
pubmed: 27861378
Liver Int. 2012 Jul;32(6):902-10
pubmed: 22435761
Blood. 2011 May 12;117(19):5112-22
pubmed: 21403126
Clin Diagn Lab Immunol. 2005 Sep;12(9):1013-9
pubmed: 16148165
Clin Mol Hepatol. 2017 Mar;23(1):1-12
pubmed: 28268262
Front Immunol. 2016 May 30;7:211
pubmed: 27303405
AIDS. 2017 Jul 17;31(11):1621-1632
pubmed: 28398960
Clin Res Hepatol Gastroenterol. 2012 Feb;36(1):13-20
pubmed: 21920839
Aliment Pharmacol Ther. 2015 Feb;41(4):368-78
pubmed: 25496369
AIDS. 2016 Nov 28;30(18):2737-2751
pubmed: 27755100
J Infect Dis. 2015 Aug 1;212(3):355-66
pubmed: 25616404
Front Immunol. 2016 Jun 20;7:228
pubmed: 27379092
Metabolism. 2016 Aug;65(8):1038-48
pubmed: 26823198
J Infect Dis. 2013 Oct 15;208(8):1194-201
pubmed: 23878320
J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):420-7
pubmed: 21266909
Clin Infect Dis. 2008 Jul 15;47(2):250-7
pubmed: 18532884
Curr HIV/AIDS Rep. 2018 Jun;15(3):212-222
pubmed: 29671204
Blood. 1998 Sep 15;92(6):2084-92
pubmed: 9731066
Curr Opin HIV AIDS. 2010 Mar;5(2):146-50
pubmed: 20543592
Clin Liver Dis. 2018 Feb;22(1):39-57
pubmed: 29128060
AIDS Res Ther. 2016 Apr 11;13:19
pubmed: 27073405
J Cell Physiol. 2012 Feb;227(2):493-507
pubmed: 21465481
ISRN Inflamm. 2013 Dec 22;2013:139239
pubmed: 24455420
J Infect Dis. 2013 Aug 15;208(4):679-89
pubmed: 23687224